Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination

Pejoski D, de Rham C, Martinez-Murillo P, Santoro F, Auderset F, Medaglini D, Pozzi G, Vono M, Lambert PH, Huttner A, Haks MC, Ottenhoff THM, Villard J, Siegrist CA, VEBCON Consortium, VSV-EBOVAC Consortium, VSV-EBOPLUS Consortium
NPJ Vaccines. 2020;5

Permenent descriptor

The rVSV-ZEBOV Ebolavirus vaccine confers protection within days after immunization, suggesting the contribution of innate immune responses. We report modulation of rVSV-ZEBOV vaccinee blood CD56(+) NK cell numbers, NKG2D or NKp30 surface receptor expression, Killer Immunoglobulin-like Receptor (KIR)(+) cell percentages and NK-cell-related genes on day 1 post immunization. Inverse correlations existed between the concentration of several plasma cytokines and inhibitory KIR(+) CD56(dim) or cytokine-responsive CD56(bright) NK cells. Thus, NK cells may contribute to the early protective efficacy of rVSV-ZEBOV in humans.